Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0000947871-18-000156
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-02-15 16:57:01
Reporting Period:
2018-02-13
Accepted Time:
2018-02-15 16:57:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1583648 Pieris Pharmaceuticals Inc. PIRS () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1055951 Orbimed Advisors Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022
No No Yes No
1432241 Orbimed Capital Gp Iii Llc 601 Lexington Avenue, 54Th Floor
New York NY 10022
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-02-13 6,057 $4.68 5,506,787 No 4 M Indirect See Footnotes
Common Stock Acquisiton 2018-02-13 58 $4.68 49,328 No 4 M Indirect See Footnotes
Common Stock Acquisiton 2018-02-13 1,765 $5.08 5,508,552 No 4 M Indirect See Footnotes
Common Stock Acquisiton 2018-02-13 17 $5.08 49,345 No 4 M Indirect See Footnotes
Common Stock Disposition 2018-02-13 7,822 $8.98 5,500,730 No 4 S Indirect See Footnotes
Common Stock Disposition 2018-02-13 75 $8.98 49,270 No 4 S Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Indirect See Footnotes
No 4 M Indirect See Footnotes
No 4 M Indirect See Footnotes
No 4 M Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2018-02-13 6,057 $0.00 6,057 $4.68
Common Stock Stock Option (right to buy) Disposition 2018-02-13 58 $0.00 58 $4.68
Common Stock Stock Option (right to buy) Disposition 2018-02-13 1,765 $0.00 1,765 $5.08
Common Stock Stock Option (right to buy) Disposition 2018-02-13 17 $0.00 17 $5.08
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2018-02-15 No 4 M Indirect
0 2018-02-15 No 4 M Indirect
0 2018-02-15 No 4 M Indirect
0 2018-02-15 No 4 M Indirect
Footnotes
  1. The stock options were included in an award to Chau Khuong, an employee of the Reporting Persons, made on October 25, 2017 for services as a director of the Issuer. The award included stock options relating to a total of 6,115 shares of the Issuer's Common Stock and was vested and exercisable on October 25, 2017. Mr. Khuong is no longer a director of the Issuer.
  2. The stock options were included in an award to Chau Khuong, an employee of the Reporting Persons, made on January 25, 2018 for services as a director of the Issuer. The award included stock options relating to a total of 1,782 shares of the Issuer's Common Stock and was vested and exercisable on January 25, 2018. Mr. Khuong is no longer a director of the Issuer.
  3. These Shares are held of record by OrbiMed Private Investments III, LP ("OPI III"). OrbiMed Capital GP III LLC ("GP III") is the general partner of OPI III, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP III. By virtue of such relationships, GP III and Advisors may be deemed to have voting and investment power over the securities held by OPI III and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by OPI III.
  4. These Shares are held of record by OrbiMed Associates III, LP ("Associates III"). Advisors is the general partner of Associates III. By virtue of such relationships, Advisors may be deemed to have voting and investment power over the securities held by Associates III and as a result may be deemed to have beneficial ownership over such securities. Advisors exercised this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the Shares held by Associates III.
  5. Samuel D. Isaly, who was included as a Reporting Person on previous reports under Section 16 of the Exchange Act filed by GP III and Advisors, is no longer subject to Section 16 with respect to securities of the Issuer.
  6. This report on Form 4 is jointly filed by GP III and Advisors. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.